Dr Göran Ando is Chairman of Tessa Therapeutics Ltd, Chairman of Eyepoint Pharmaceuticals Inc and the Chairman of Nanexa AB. He is a Director of Paraxel International Corp. Göran also serves as Senior Advisor to Essex Woodlands Health Ventures LLC, an Advisor to Edbi Pte Ltd, Singapore and is a Non-Executive Director of EUSA Pharma (UK) Ltd and Selectra Biosciences Inc.
Dr Göran Ando MD, is the retired Chairman of the Board of Directors of Novo Nordisk A/S and was previously a member of the Board at Novo Holdings A/S, Denmark. Göran was Vice Chairman of the Board at Molecular Partners AG, Zurich and has extensive board experience in Europe and Asia.
Göran is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US.
From 1989 to 1995, Göran was Medical Director, moving to Deputy R&D Director and then R&D Director of Glaxo Group Limited. He was also a member of the Glaxo Group Executive Committee.
From 1995 to 2003 he was part of Pharmacia Corp, now Pfizer US, where he was Executive Vice-President and President of R&D with additional responsibilities for manufacturing, IT, business development and Mergers & Acquisitions.
Göran was CEO of Celltech Group plc UK and Chairman of the Board at Symphogen A/S.